Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03672773 · ClinicalTrials.gov registry record · Phase 2
Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
A Phase 2 study of Recurrent Extensive Stage Small Cell Lung Carcinoma and Refractory Extensive Stage Small Cell Lung Carcinoma, sponsored by Jonsson Comprehensive Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 6
- Study locations
NCT03672773 is a Phase 2 study of Recurrent Extensive Stage Small Cell Lung Carcinoma and Refractory Extensive Stage Small Cell Lung Carcinoma that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 35 participants. The trial reports 6 study locations across 4 states.
The verdict
NCT03672773, a Phase 2 study of Recurrent Extensive Stage Small Cell Lung Carcinoma and Refractory Extensive Stage Small Cell Lung Carcinoma, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 6
- Study locations
Study Summary
This phase II trial studies how effective talazoparib and temozolomide are for treating participants with extensive-stage small cell lung cancer that has come back after an initial chemotherapy treatment. Talazoparib, a PARP inhibitor, may stop the growth of tumor cells by preventing them from repairing their DNA. Chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving talazoparib and temozolomide may work better in treating participants with extensive-stage small cell lung cancer than either one alone.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Talazoparib
Study Locations (6)
California
- CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center - Bakersfield
- St. Joseph Heritage Healthcare - Fullerton
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Florida
- Orlando Health, Inc. d/b/a Orlando Health UF Health Center - Orlando
Indiana
- Ft. Wayne Medical Oncology and Hematology, Inc. - Fort Wayne
Kansas
- Cancer Center of Kansas - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2018-10-31 |
| Est. Completion | 2027-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03672773
The ClinicalTrials.gov registry entry for NCT03672773 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Extensive Stage Small Cell Lung Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Temozolomide is the first listed.
NCT03672773 reports 6 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT03672773 about?
NCT03672773 is a clinical study titled "Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer". This phase II trial studies how effective talazoparib and temozolomide are for treating participants with extensive-stage small cell lung cancer that has come back after an initial chemotherapy treatment. Talazoparib, a PARP inhibitor, may stop the growth of tumor cells by preventing them from repai...
What is the current status of trial NCT03672773?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2018-10-31. Estimated completion is 2027-10-01.
What conditions does trial NCT03672773 study?
This clinical trial studies the following conditions: Recurrent Extensive Stage Small Cell Lung Carcinoma, Refractory Extensive Stage Small Cell Lung Carcinoma.
What interventions are being tested in trial NCT03672773?
The interventions under investigation include: Temozolomide (DRUG), Talazoparib (DRUG).
Who is sponsoring clinical trial NCT03672773?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03672773 being conducted?
This trial has 6 study locations across California, Florida, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Recurrent Extensive Stage Small Cell Lung Carcinoma
All registered trials for this condition
Refractory Extensive Stage Small Cell Lung Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.